Pomegra
Surgery Partners stock surged about 21% premarket as Bon Secours Mercy Health neared a roughly $6B majority-stake deal, including debt, for the Bain-backed chain.
- Surgery Partners (SGRY) rose about 21% premarket to roughly $19 on the Financial Times report.
- Bon Secours is in late-stage talks for a majority stake valuing the company at about $6B including debt.
- The reported price of about $20 a share is a premium of roughly 26% to the prior close.
Lead
Surgery Partners (NASDAQ: SGRY) shares jumped about 21% in premarket trading on Monday, October 26, after the Financial Times reported that Bon Secours Mercy Health is in late-stage talks to buy a majority stake in the surgical care provider. The transaction would value the company at about $6 billion, including roughly $3.5 billion of debt. Shares traded near $19.00 before the open.What Happened to Surgery Partners Stock?
Surgery Partners stock climbed roughly 20.6% to about $19.00 in premarket trading after the report was published on Sunday. That is just under the reported deal price of about $20 a share, which implies a premium of around 26% to Friday's close.
The gap between the premarket price and the implied offer reflects the remaining uncertainty. Talks have not produced a signed agreement, and the terms could change.
What Would the Deal Look Like?
The deal would give Bon Secours control of Surgery Partners while leaving its largest existing shareholder in place. Bain Capital, which has held a stake since 2017, would keep its stake of nearly 40%.
Bon Secours is one of the largest not-for-profit health systems in the United States. It runs 47 hospitals across the United States and Ireland and generated about $14 billion in revenue last year. Surgery Partners operates 176 surgery centers and hospitals in 30 states.
Why Does Bon Secours Want Surgery Partners?
The move would speed up Bon Secours' expansion into outpatient care. Procedures that once required an inpatient stay increasingly move to ambulatory surgery centers, which usually cost less and are favored by insurers and patients. Buying an established national network is faster than building one site by site.
For a nonprofit system, a majority position in a publicly listed, private-equity-backed operator would be an unusual structure. It would combine the system's hospital referral base with a for-profit outpatient platform.
Strategic Context for Bain Capital
A sale would end more than a year of stop-start efforts to exit the investment. Bain tried to acquire the whole company in 2025 at an enterprise value of about $6.7 billion, but those talks collapsed. The current structure is a partial sale, with Bain keeping its roughly 40% stake and retaining exposure to future gains in the business.
The roughly $3.5 billion of debt makes up more than half of the headline valuation. The equity value implied by the deal is therefore much smaller than the $6 billion figure suggests.
What Comes Next for the Sale Process?
The next step is a definitive agreement, which would set the price, the structure of the stake purchase and the governance arrangement with Bain. A deal of this size would likely need regulatory clearance, including antitrust review, and a shareholder vote or tender process for the public float.
Neither company has confirmed the talks. If a deal is announced, the key details will be the final per-share price, whether minority shareholders are offered the same terms, and how Bon Secours plans to finance the purchase.
Outlook
Surgery Partners shares now trade as a takeover situation, priced just below the reported $20 offer. A signed agreement would close a long-running sale effort for Bain Capital and mark a significant push into outpatient surgery for Bon Secours Mercy Health. The talks could still stall, as the 2025 attempt did, so the premarket gap to the reported price shows how much risk the market still sees.
Mentioned tickers: SGRY
